Index -
P/E -
EPS (ttm) -
Insider Own 29.61%
Shs Outstand 43.12M
Perf Week -6.21%
Market Cap 716.22M
Forward P/E -
EPS next Y -4.00
Insider Trans 19.27%
Shs Float 30.35M
Perf Month -27.47%
Income -
PEG -
EPS next Q -0.84
Inst Own 3.27%
Short Float 5.13%
Perf Quarter -
Sales -
P/S -
EPS this Y 96.35%
Inst Trans -
Short Ratio 3.11
Perf Half Y -
Book/sh -3.05
P/B -
EPS next Y -22.14%
ROA -
Short Interest 1.56M
Perf Year -
Cash/sh 1.33
P/C 12.45
EPS next 5Y -
ROE -
52W Range 13.96 - 35.06
Perf YTD -44.63%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -
52W High -52.62%
Beta -
Dividend TTM -
Quick Ratio 3.05
Sales past 5Y -37.90%
Gross Margin -
52W Low 18.98%
ATR (14) 1.56
Dividend Ex-Date -
Current Ratio 3.05
EPS Y/Y TTM -
Oper. Margin -
RSI (14) 33.05
Volatility 9.90% 7.63%
Employees 96
Debt/Eq 0.18
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 42.75
Option/Short Yes / Yes
LT Debt/Eq 0.13
EPS Q/Q -
Payout -
Rel Volume 1.46
Prev Close 15.14
Sales Surprise -
EPS Surprise -2819.81%
Sales Q/Q -
Earnings Mar 26 AMC
Avg Volume 500.49K
Price 16.61
SMA20 -18.29%
SMA50 -31.91%
SMA200 -33.72%
Trades
Volume 731,696
Change 9.71%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-04-24 Initiated
Wells Fargo
Overweight
$44
Mar-04-24 Initiated
Morgan Stanley
Overweight
$40
Mar-04-24 Initiated
Leerink Partners
Outperform
$48
Mar-04-24 Initiated
JP Morgan
Overweight
$39
Apr-11-24 05:01PM
Mar-29-24 02:59PM
Mar-26-24 04:05PM
Mar-14-24 07:00AM
(The Wall Street Journal)
Mar-07-24 07:26PM
06:14PM
Loading…
06:14PM
Feb-12-24 04:39PM
Feb-07-24 10:29PM
Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company. It develops treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
GILEAD SCIENCES, INC. 10% Owner Feb 12 '24 Buy 22.00 910,000 20,020,000 4,126,119 Feb 13 05:48 PM Northpond Ventures III GP, LLC Former 10% Owner Feb 12 '24 Buy 22.00 450,000 9,900,000 450,000 Feb 12 05:51 PM Bain Capital Life Sciences Inv 10% Owner Feb 12 '24 Buy 22.00 450,000 9,900,000 3,163,868 Feb 14 05:26 PM Vida Ventures, LLC 10% Owner Feb 12 '24 Buy 22.00 253,136 5,568,992 252,553 Feb 14 07:04 PM
Index RUT
P/E -
EPS (ttm) -3.72
Insider Own 15.70%
Shs Outstand 32.49M
Perf Week 1.34%
Market Cap 520.27M
Forward P/E -
EPS next Y -1.91
Insider Trans -0.39%
Shs Float 30.46M
Perf Month 2.20%
Income -102.24M
PEG -
EPS next Q -0.87
Inst Own 67.00%
Short Float 13.79%
Perf Quarter -8.28%
Sales 82.71M
P/S 6.29
EPS this Y -1.97%
Inst Trans -0.56%
Short Ratio 11.62
Perf Half Y 32.47%
Book/sh -2.01
P/B -
EPS next Y 47.29%
ROA -65.14%
Short Interest 4.20M
Perf Year 0.77%
Cash/sh 3.81
P/C 3.78
EPS next 5Y -
ROE -
52W Range 8.69 - 24.13
Perf YTD -4.00%
Dividend Est. -
P/FCF -
EPS past 5Y 5.89%
ROI -299.11%
52W High -40.32%
Beta 1.09
Dividend TTM -
Quick Ratio 5.24
Sales past 5Y 13144.25%
Gross Margin 88.68%
52W Low 65.71%
ATR (14) 0.88
Dividend Ex-Date -
Current Ratio 5.42
EPS Y/Y TTM 22.21%
Oper. Margin -79.23%
RSI (14) 49.35
Volatility 4.78% 6.10%
Employees 201
Debt/Eq -
Sales Y/Y TTM 28.52%
Profit Margin -123.61%
Recom 1.40
Target Price 38.50
Option/Short Yes / Yes
LT Debt/Eq -
EPS Q/Q 41.19%
Payout -
Rel Volume 0.50
Prev Close 13.82
Sales Surprise 4.26%
EPS Surprise -5.88%
Sales Q/Q 30.06%
Earnings Mar 14 BMO
Avg Volume 361.29K
Price 14.40
SMA20 3.03%
SMA50 -7.56%
SMA200 -5.32%
Trades
Volume 179,883
Change 4.20%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-08-23 Downgrade
Jefferies
Buy → Hold
$35 → $10
Apr-27-22 Initiated
Berenberg
Buy
$20
Apr-16-20 Reiterated
H.C. Wainwright
Buy
$53 → $57
Apr-13-20 Reiterated
H.C. Wainwright
Buy
$75 → $53
Jan-09-20 Initiated
National Securities
Neutral
$37
May-30-19 Initiated
JP Morgan
Neutral
May-29-19 Initiated
Goldman
Neutral
Jan-29-19 Initiated
H.C. Wainwright
Buy
$82
Nov-08-18 Resumed
Jefferies
Buy
Apr-04-18 Upgrade
Raymond James
Mkt Perform → Outperform
Jan-02-18 Initiated
Ladenburg Thalmann
Buy
$50
Nov-15-17 Reiterated
Oppenheimer
Outperform
$32 → $51
Nov-15-17 Downgrade
Raymond James
Outperform → Mkt Perform
Show Previous Ratings
Apr-17-24 12:02PM
Apr-15-24 08:00AM
Apr-03-24 08:00AM
Mar-15-24 10:30AM
Mar-14-24 12:53PM
09:32AM
Loading…
09:32AM
09:10AM
08:00AM
Mar-08-24 08:00AM
Mar-04-24 08:00AM
Feb-26-24 08:00AM
Feb-01-24 08:00AM
Jan-24-24 08:00AM
Jan-17-24 08:00AM
Jan-11-24 08:00AM
04:00PM
Loading…
Dec-08-23 04:00PM
Nov-15-23 01:50PM
Nov-14-23 12:19PM
08:00AM
Nov-13-23 08:00AM
Nov-07-23 08:00AM
Oct-03-23 08:00AM
Sep-11-23 07:00AM
Sep-08-23 08:00AM
Aug-31-23 08:00AM
Aug-18-23 01:40PM
Aug-17-23 07:00AM
(The Wall Street Journal) -14.16%
Aug-12-23 09:18AM
Aug-10-23 09:55AM
09:15AM
08:00AM
Loading…
08:00AM
Aug-08-23 08:00AM
Aug-02-23 05:00PM
Aug-01-23 10:05AM
Jul-31-23 08:00AM
Jul-28-23 01:41PM
Jul-27-23 09:55AM
09:50AM
Jul-25-23 04:10PM
Jul-10-23 08:00AM
Jul-06-23 08:00AM
Jun-20-23 08:00AM
Jun-09-23 08:00AM
Jun-02-23 08:00AM
May-22-23 01:18PM
May-16-23 12:13PM
May-11-23 09:15AM
08:00AM
May-04-23 08:00AM
May-02-23 10:02AM
May-01-23 02:00PM
Apr-30-23 08:00AM
Apr-25-23 08:00AM
Apr-18-23 12:16PM
Mar-18-23 02:06AM
Mar-16-23 09:15AM
08:00AM
Mar-09-23 04:00PM
Mar-06-23 08:00AM
Mar-01-23 04:00PM
Feb-27-23 08:15AM
Feb-15-23 09:06AM
Feb-06-23 05:33AM
Jan-11-23 08:00AM
Jan-09-23 12:19PM
Dec-19-22 08:00AM
Dec-13-22 12:13PM
Dec-09-22 08:00AM
Dec-02-22 12:00PM
Dec-01-22 07:00PM
Nov-21-22 04:00PM
Nov-16-22 11:24AM
Nov-14-22 08:00AM
Nov-12-22 07:33AM
Nov-10-22 09:15AM
08:00AM
Nov-09-22 08:00AM
Nov-03-22 08:00AM
Oct-12-22 04:29AM
Oct-11-22 11:54AM
08:00AM
Sep-28-22 08:00AM
Sep-12-22 08:00AM
Sep-09-22 08:00AM
Sep-07-22 04:00PM
Aug-11-22 09:15AM
08:00AM
Jul-27-22 08:00AM
Jul-24-22 09:56AM
Jul-12-22 09:05AM
Jun-09-22 09:07AM
Jun-03-22 08:00AM
May-18-22 08:00AM
May-16-22 02:50PM
May-13-22 08:00AM
May-10-22 10:15AM
09:00AM
08:00AM
May-09-22 06:15PM
May-05-22 06:35PM
UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Schoenberg Mark Chief Medical Officer Mar 18 '24 Sale 14.05 12,000 168,600 139,437 Mar 20 04:38 PM Smith Jason Drew General Counsel Jan 31 '24 Sale 15.74 4,993 78,590 18,824 Feb 02 07:12 PM Schoenberg Mark Chief Medical Officer Jan 31 '24 Sale 15.74 3,789 59,639 149,423 Feb 02 07:07 PM Smith Jason Drew General Counsel Aug 31 '23 Sale 18.01 3,800 68,438 18,407 Sep 05 04:28 PM
Index RUT
P/E -
EPS (ttm) -3.55
Insider Own 6.04%
Shs Outstand 51.50M
Perf Week 15.04%
Market Cap 475.34M
Forward P/E -
EPS next Y -1.32
Insider Trans 0.00%
Shs Float 48.65M
Perf Month -7.74%
Income -190.28M
PEG -
EPS next Q -0.47
Inst Own 101.49%
Short Float 9.65%
Perf Quarter 7.24%
Sales 280.32M
P/S 1.70
EPS this Y 55.36%
Inst Trans -1.83%
Short Ratio 5.93
Perf Half Y 78.25%
Book/sh 5.07
P/B 1.81
EPS next Y 16.67%
ROA -36.40%
Short Interest 4.69M
Perf Year 10.60%
Cash/sh 4.55
P/C 2.02
EPS next 5Y 20.00%
ROE -54.98%
52W Range 4.80 - 12.93
Perf YTD -23.50%
Dividend Est. -
P/FCF -
EPS past 5Y -21.96%
ROI -65.70%
52W High -29.00%
Beta 1.51
Dividend TTM -
Quick Ratio 3.77
Sales past 5Y 33.42%
Gross Margin 62.74%
52W Low 91.25%
ATR (14) 0.68
Dividend Ex-Date -
Current Ratio 4.02
EPS Y/Y TTM -147.12%
Oper. Margin -37.01%
RSI (14) 54.07
Volatility 9.13% 6.09%
Employees 643
Debt/Eq 0.13
Sales Y/Y TTM -12.89%
Profit Margin -67.88%
Recom 1.71
Target Price 13.00
Option/Short Yes / Yes
LT Debt/Eq 0.11
EPS Q/Q -546.03%
Payout -
Rel Volume 3.29
Prev Close 7.76
Sales Surprise 3.00%
EPS Surprise -394.74%
Sales Q/Q -20.41%
Earnings May 09 AMC
Avg Volume 791.33K
Price 9.18
SMA20 6.71%
SMA50 -3.94%
SMA200 1.17%
Trades
Volume 2,599,703
Change 18.30%
Date
Action
Analyst
Rating Change
Price Target Change
Today Upgrade
Craig Hallum
Hold → Buy
$15
Nov-09-23 Upgrade
Stephens
Equal-Weight → Overweight
$10
Aug-15-23 Upgrade
Raymond James
Mkt Perform → Outperform
$12
May-11-23 Downgrade
BTIG Research
Buy → Neutral
Mar-07-23 Downgrade
Stephens
Overweight → Equal-Weight
$19 → $9
Mar-03-23 Downgrade
Raymond James
Strong Buy → Mkt Perform
Mar-03-23 Downgrade
Craig Hallum
Buy → Hold
$26 → $9
Apr-25-22 Initiated
Stephens
Overweight
$50
Jul-20-21 Resumed
BTIG Research
Buy
$115
Jun-03-21 Initiated
Goldman
Buy
$95
Feb-26-21 Downgrade
H.C. Wainwright
Buy → Neutral
Oct-30-20 Reiterated
H.C. Wainwright
Buy
$47 → $55
Oct-08-20 Reiterated
H.C. Wainwright
Buy
$45 → $47
Oct-02-20 Reiterated
H.C. Wainwright
Buy
$40 → $45
Aug-05-20 Reiterated
H.C. Wainwright
Buy
$37 → $40
Jun-26-20 Initiated
BTIG Research
Buy
$40
Jun-19-20 Reiterated
H.C. Wainwright
Buy
$40 → $37
Oct-01-19 Resumed
Craig Hallum
Buy
$48
May-09-19 Upgrade
H.C. Wainwright
Neutral → Buy
$30 → $43
Feb-15-19 Initiated
Jefferies
Buy
$35
Show Previous Ratings
Apr-29-24 04:05PM
Apr-19-24 04:05PM
Apr-18-24 03:47AM
Apr-16-24 04:02PM
Apr-09-24 07:00AM
08:40AM
Loading…
Apr-01-24 08:40AM
Mar-11-24 04:10PM
Feb-29-24 10:43AM
06:59AM
(Thomson Reuters StreetEvents)
Feb-28-24 07:00PM
05:28PM
(Associated Press Finance)
04:57PM
04:05PM
Feb-27-24 04:05PM
Feb-26-24 09:15AM
04:05PM
Loading…
Feb-21-24 04:05PM
07:00AM
Jan-26-24 09:45PM
Jan-11-24 04:05PM
Jan-09-24 07:00AM
Dec-19-23 07:00AM
Dec-08-23 09:55AM
Nov-22-23 09:55AM
Nov-10-23 10:15AM
Nov-08-23 05:02PM
(Associated Press Finance)
04:05PM
Nov-06-23 07:38AM
Nov-02-23 04:05PM
Nov-01-23 04:02PM
Oct-17-23 07:00AM
07:12PM
Loading…
Oct-03-23 07:12PM
06:00PM
04:43PM
Oct-02-23 11:06AM
Sep-19-23 07:00AM
Sep-14-23 02:00AM
Aug-31-23 07:00AM
Aug-17-23 07:00AM
Aug-15-23 09:59AM
Aug-11-23 07:00AM
Aug-09-23 09:30AM
Aug-08-23 06:05PM
05:02PM
04:05PM
Aug-07-23 11:08AM
Aug-03-23 07:00AM
Aug-02-23 07:00AM
Jul-25-23 07:00AM
Jul-17-23 11:42PM
Jul-11-23 07:00AM
Jul-10-23 08:44AM
Jul-07-23 12:26PM
Jul-05-23 06:08AM
Jun-01-23 08:00AM
07:00AM
May-16-23 07:00AM
06:42AM
06:02AM
May-11-23 10:13AM
(Thomson Reuters StreetEvents)
May-10-23 05:45PM
04:43PM
04:05PM
May-08-23 07:01AM
Apr-25-23 06:01AM
Apr-19-23 07:01AM
Apr-18-23 01:22PM
Apr-06-23 07:01AM
Apr-05-23 06:55AM
Mar-23-23 07:01AM
Mar-11-23 02:46AM
Mar-07-23 07:01AM
Mar-06-23 04:32PM
07:01AM
Mar-03-23 04:01PM
07:01AM
Mar-01-23 07:01AM
05:19AM
Feb-28-23 09:58AM
(Thomson Reuters StreetEvents) +14.34%
Feb-27-23 05:15PM
04:01PM
06:28AM
Feb-22-23 07:01AM
Feb-21-23 04:01PM
Feb-20-23 10:00AM
Feb-16-23 10:01AM
07:01AM
Feb-01-23 09:48AM
Jan-27-23 08:30AM
Jan-26-23 08:21AM
07:01AM
Jan-11-23 07:01AM
Jan-09-23 07:00AM
Dec-21-22 06:00PM
Dec-14-22 07:00AM
Dec-06-22 08:01AM
Dec-05-22 03:49PM
Dec-01-22 08:15AM
Nov-17-22 09:55AM
Nov-11-22 09:35AM
07:01AM
CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. Its products include AlloMap, AlloSure and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Maag Peter Director Apr 29 '24 Option Exercise 5.27 13,281 69,991 327,264 May 01 04:38 PM Seeto Reginald See Remarks Oct 02 '23 Sale 6.91 2,818 19,483 479,164 Oct 02 07:53 PM Seeto Reginald See Remarks Sep 05 '23 Sale 9.49 2,819 26,762 481,982 Sep 05 04:03 PM Seeto Reginald See Remarks Aug 14 '23 Sale 8.89 576 5,123 484,801 Aug 14 07:52 PM Bickerstaff George Director Aug 11 '23 Option Exercise 5.09 19,453 99,065 99,721 Aug 11 07:47 PM Seeto Reginald See Remarks Aug 02 '23 Sale 11.35 2,819 31,988 486,051 Aug 02 06:53 PM Seeto Reginald See Remarks Jul 13 '23 Sale 10.33 5,260 54,357 488,870 Jul 13 08:56 PM Maag Peter Director Jul 13 '23 Sale 10.34 5,000 51,680 309,657 Jul 13 08:56 PM Seeto Reginald See Remarks Jul 03 '23 Sale 8.48 2,818 23,901 498,055 Jul 03 05:19 PM Seeto Reginald See Remarks Jun 28 '23 Sale 8.76 14,268 125,016 500,873 Jun 28 08:44 PM Maag Peter Director Jun 28 '23 Sale 8.72 2,432 21,216 313,136 Jun 28 08:43 PM Seeto Reginald See Remarks Jun 02 '23 Sale 8.13 2,819 22,911 532,177 Jun 02 08:08 PM Seeto Reginald See Remarks May 02 '23 Sale 8.12 2,819 22,898 534,996 May 04 05:36 PM
Index RUT
P/E -
EPS (ttm) -5.42
Insider Own 2.33%
Shs Outstand 96.44M
Perf Week 6.28%
Market Cap 2.17B
Forward P/E -
EPS next Y -5.64
Insider Trans -2.33%
Shs Float 94.19M
Perf Month -10.36%
Income -481.19M
PEG -
EPS next Q -1.37
Inst Own 88.81%
Short Float 15.49%
Perf Quarter -5.54%
Sales 36.27M
P/S 59.83
EPS this Y -1.29%
Inst Trans -0.30%
Short Ratio 9.68
Perf Half Y -5.58%
Book/sh 11.29
P/B 1.99
EPS next Y -2.69%
ROA -34.11%
Short Interest 14.59M
Perf Year -40.38%
Cash/sh 9.46
P/C 2.38
EPS next 5Y 30.00%
ROE -42.10%
52W Range 19.37 - 47.48
Perf YTD -26.21%
Dividend Est. -
P/FCF -
EPS past 5Y -22.30%
ROI -41.96%
52W High -52.61%
Beta 1.85
Dividend TTM -
Quick Ratio 8.67
Sales past 5Y 12.09%
Gross Margin 75.26%
52W Low 16.16%
ATR (14) 1.31
Dividend Ex-Date -
Current Ratio 8.67
EPS Y/Y TTM 12.31%
Oper. Margin -1420.51%
RSI (14) 44.72
Volatility 6.72% 4.90%
Employees 526
Debt/Eq 0.11
Sales Y/Y TTM -30.40%
Profit Margin -1326.51%
Recom 1.54
Target Price 69.57
Option/Short Yes / Yes
LT Debt/Eq 0.09
EPS Q/Q -4.64%
Payout -
Rel Volume 1.12
Prev Close 21.40
Sales Surprise -115.04%
EPS Surprise -1.49%
Sales Q/Q -114.12%
Earnings Feb 22 BMO
Avg Volume 1.51M
Price 22.50
SMA20 -1.78%
SMA50 -14.34%
SMA200 -25.96%
Trades
Volume 1,684,893
Change 5.14%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-23-24 Downgrade
Goldman
Buy → Neutral
$136 → $32
Feb-15-24 Initiated
Wolfe Research
Peer Perform
Apr-13-23 Initiated
Canaccord Genuity
Buy
$66
Mar-21-23 Initiated
Bernstein
Outperform
$54
Mar-14-23 Upgrade
BMO Capital Markets
Market Perform → Outperform
$54 → $57
Feb-01-23 Initiated
Cantor Fitzgerald
Overweight
$67
Jan-24-23 Upgrade
Citigroup
Sell → Neutral
$48 → $39
Jan-19-23 Downgrade
JMP Securities
Mkt Outperform → Mkt Perform
Oct-11-22 Initiated
Morgan Stanley
Overweight
$84
Sep-21-22 Initiated
JP Morgan
Overweight
$85
Sep-01-22 Initiated
Citigroup
Sell
$50
Jun-17-22 Initiated
BMO Capital Markets
Market Perform
$54
Jun-16-22 Initiated
BofA Securities
Buy
$70
Apr-28-22 Initiated
Credit Suisse
Outperform
$100
Feb-18-22 Initiated
William Blair
Outperform
$144
Feb-07-22 Upgrade
Oppenheimer
Perform → Outperform
$145 → $150
Jan-31-22 Initiated
Cowen
Outperform
Jan-07-22 Initiated
Piper Sandler
Overweight
$171
Oct-05-21 Initiated
Guggenheim
Buy
$170
Sep-24-21 Initiated
Stifel
Buy
$173
Show Previous Ratings
Apr-29-24 07:30AM
Apr-25-24 11:21AM
10:01AM
Apr-14-24 05:55AM
Apr-12-24 04:50AM
04:50AM
Loading…
Apr-09-24 04:50AM
Mar-28-24 05:55AM
Mar-21-24 05:29PM
04:19PM
Mar-19-24 01:06PM
Mar-18-24 07:30AM
Mar-09-24 09:45AM
Mar-06-24 10:35AM
Mar-01-24 01:43PM
Feb-29-24 05:50AM
09:30AM
Loading…
Feb-28-24 09:30AM
Feb-27-24 11:55AM
09:35AM
Feb-23-24 12:22PM
11:12AM
09:55AM
Feb-22-24 10:53PM
(Thomson Reuters StreetEvents)
08:12AM
07:30AM
Feb-20-24 05:02AM
Feb-17-24 01:59AM
Feb-15-24 10:00AM
07:30AM
06:20AM
Feb-14-24 07:30AM
06:05AM
Loading…
Feb-13-24 06:05AM
Feb-10-24 05:09PM
Feb-08-24 01:15PM
Feb-07-24 11:50AM
Feb-05-24 05:25AM
Jan-31-24 05:00PM
12:28PM
Jan-30-24 05:10AM
Jan-29-24 09:35AM
Jan-27-24 01:25PM
08:55AM
Jan-24-24 07:00AM
Jan-22-24 05:41PM
Jan-21-24 08:00AM
Jan-18-24 11:50AM
Jan-13-24 06:05AM
Jan-12-24 08:44AM
Jan-08-24 07:45AM
05:52AM
Jan-05-24 10:04AM
Jan-04-24 04:01PM
12:47PM
Dec-31-23 08:45AM
Dec-27-23 06:41PM
Dec-16-23 05:00AM
Dec-13-23 05:20AM
Dec-12-23 06:00AM
Dec-10-23 11:57AM
Nov-28-23 05:30AM
Nov-24-23 07:00AM
(The Wall Street Journal)
Nov-15-23 11:07AM
Nov-14-23 07:30AM
Nov-10-23 05:38PM
06:30AM
Nov-09-23 04:06PM
03:37PM
08:29AM
07:30AM
Nov-06-23 08:02AM
(Investor's Business Daily)
Nov-02-23 07:00AM
06:45AM
Oct-30-23 03:46PM
10:00AM
Oct-28-23 07:30AM
Oct-26-23 10:02AM
07:30AM
Oct-23-23 09:40AM
08:45AM
Oct-21-23 05:00AM
Oct-19-23 11:46AM
Oct-18-23 04:10PM
(Investor's Business Daily)
07:00AM
Oct-16-23 12:39PM
10:43AM
Oct-14-23 12:20PM
Oct-13-23 08:38AM
Oct-12-23 08:57AM
Oct-10-23 02:00PM
10:07AM
Oct-06-23 04:59AM
Oct-05-23 09:15AM
Oct-04-23 09:27AM
Oct-03-23 10:07AM
07:58AM
07:08AM
07:00AM
Sep-23-23 09:45AM
Sep-10-23 08:15AM
Sep-09-23 03:59PM
Sep-06-23 02:00PM
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
BASTA JAMES EVP, General Counsel Mar 04 '24 Sale 32.99 2,297 75,778 81,571 Mar 05 04:10 PM Clark Eliana EVP, Chief Technical Officer Mar 04 '24 Sale 32.99 605 19,959 71,470 Mar 05 04:10 PM Sepp-Lorenzino Laura EVP, Chief Scientific Officer Jan 08 '24 Sale 28.87 2,275 65,682 43,927 Jan 10 04:15 PM LEONARD JOHN M President and CEO Jan 03 '24 Sale 29.46 19,223 566,310 846,486 Jan 05 04:51 PM Lebwohl David EVP, Chief Medical Officer Jan 03 '24 Sale 29.46 5,843 172,135 54,372 Jan 05 04:50 PM Sepp-Lorenzino Laura EVP, Chief Scientific Officer Jan 03 '24 Sale 29.46 5,532 162,973 46,202 Jan 05 04:50 PM Goddard Glenn EVP, Chief Financial Officer Jan 03 '24 Sale 29.46 5,365 158,053 40,585 Jan 05 04:49 PM Clark Eliana EVP, Chief Technical Officer Jan 03 '24 Sale 29.50 4,608 135,954 40,845 Jan 05 04:44 PM Hicks Derek EVP, Chief Business Officer Jan 03 '24 Sale 29.46 3,877 114,216 36,987 Jan 05 04:46 PM BASTA JAMES EVP, General Counsel Jan 03 '24 Sale 29.46 3,805 112,095 51,474 Jan 05 04:45 PM Bhanji Muna Director Oct 31 '23 Sale 23.90 265 6,334 11,996 Nov 02 04:42 PM Bhanji Muna Director Jul 31 '23 Sale 42.33 265 11,217 12,261 Aug 02 05:19 PM Bhanji Muna Director Jul 06 '23 Sale 39.30 1,867 73,373 12,526 Jul 10 05:21 PM Clark Eliana EVP, Chief Technical Officer Jul 03 '23 Sale 40.51 360 14,584 45,146 Jul 06 03:34 PM Clark Eliana EVP, Chief Technical Officer Jun 20 '23 Option Exercise 12.27 5,000 61,350 50,146 Jun 22 05:52 PM Clark Eliana EVP, Chief Technical Officer Jun 20 '23 Sale 45.00 5,000 225,000 45,146 Jun 22 05:52 PM
Index RUT
P/E 52.35
EPS (ttm) 0.62
Insider Own 13.90%
Shs Outstand 95.73M
Perf Week -0.95%
Market Cap 3.12B
Forward P/E 32.52
EPS next Y 0.99
Insider Trans -4.84%
Shs Float 83.09M
Perf Month -9.48%
Income 62.04M
PEG 3.71
EPS next Q 0.13
Inst Own 87.20%
Short Float 7.95%
Perf Quarter -15.23%
Sales 1.09B
P/S 2.86
EPS this Y 12.03%
Inst Trans -1.63%
Short Ratio 7.76
Perf Half Y 4.13%
Book/sh 5.78
P/B 5.59
EPS next Y 42.95%
ROA 9.48%
Short Interest 6.60M
Perf Year -3.87%
Cash/sh 3.85
P/C 8.40
EPS next 5Y 14.10%
ROE 13.34%
52W Range 29.44 - 44.95
Perf YTD -13.15%
Dividend Est. -
P/FCF 16.83
EPS past 5Y -
ROI 10.87%
52W High -28.16%
Beta 1.51
Dividend TTM -
Quick Ratio 3.44
Sales past 5Y 61.75%
Gross Margin 21.94%
52W Low 9.68%
ATR (14) 0.95
Dividend Ex-Date -
Current Ratio 3.44
EPS Y/Y TTM 98.39%
Oper. Margin 5.71%
RSI (14) 37.50
Volatility 2.32% 2.44%
Employees 566
Debt/Eq 0.04
Sales Y/Y TTM 38.34%
Profit Margin 5.70%
Recom 1.10
Target Price 47.10
Option/Short Yes / Yes
LT Debt/Eq 0.03
EPS Q/Q 292.08%
Payout 0.00%
Rel Volume 1.18
Prev Close 32.06
Sales Surprise -1.51%
EPS Surprise 20.93%
Sales Q/Q 25.95%
Earnings May 09 AMC
Avg Volume 850.85K
Price 32.29
SMA20 -4.21%
SMA50 -9.19%
SMA200 -10.33%
Trades
Volume 1,001,558
Change 0.72%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-26-24 Initiated
Leerink Partners
Outperform
$49
Jan-03-24 Initiated
Barclays
Overweight
$48
Sep-27-23 Initiated
Canaccord Genuity
Buy
$46
May-22-23 Initiated
BTIG Research
Buy
$50
Apr-21-23 Initiated
Cantor Fitzgerald
Overweight
$44
Jan-05-23 Downgrade
SVB Leerink
Outperform → Mkt Perform
$34
Sep-16-22 Initiated
KeyBanc Capital Markets
Overweight
$55
Sep-07-22 Initiated
Truist
Buy
$56
Dec-02-21 Initiated
Jefferies
Buy
$60
Nov-22-21 Downgrade
Citigroup
Buy → Neutral
$60 → $64
Sep-30-21 Initiated
Berenberg
Buy
$81
Aug-12-21 Initiated
Barclays
Overweight
$64
Jun-02-21 Downgrade
Guggenheim
Buy → Neutral
Apr-29-21 Resumed
JP Morgan
Overweight
$65
Mar-10-21 Upgrade
BofA Securities
Neutral → Buy
$53
Jul-01-20 Initiated
SVB Leerink
Outperform
$35
Jun-02-20 Initiated
Guggenheim
Buy
$30
Nov-19-19 Initiated
SVB Leerink
Outperform
$28
Nov-19-19 Initiated
Piper Jaffray
Overweight
$33
Nov-19-19 Initiated
JP Morgan
Overweight
$26
Show Previous Ratings
Apr-25-24 02:00PM
Apr-17-24 09:23AM
Apr-13-24 12:18PM
Apr-04-24 08:59AM
Apr-03-24 07:01PM
01:30AM
Loading…
Mar-30-24 01:30AM
Mar-28-24 08:13AM
01:37AM
Mar-26-24 07:49AM
Mar-18-24 12:00PM
Mar-13-24 04:30PM
Mar-11-24 12:00PM
Feb-29-24 05:48PM
07:30AM
Feb-28-24 10:41AM
10:15AM
Loading…
10:15AM
09:01AM
07:19AM
(Thomson Reuters StreetEvents)
Feb-27-24 05:11PM
(Associated Press Finance)
04:34PM
04:01PM
Feb-13-24 04:30PM
Feb-08-24 03:06AM
Feb-05-24 11:30PM
Jan-24-24 01:36PM
Jan-17-24 09:30AM
Jan-16-24 06:10PM
Jan-12-24 09:23AM
05:03AM
Jan-11-24 09:01AM
10:30AM
Loading…
Jan-08-24 10:30AM
Jan-06-24 03:12AM
Jan-05-24 03:02AM
Dec-29-23 09:01PM
Dec-24-23 03:01AM
Dec-19-23 06:49AM
05:10AM
Nov-20-23 10:17AM
Nov-13-23 12:45PM
Nov-10-23 12:00PM
Nov-09-23 03:52PM
Nov-07-23 05:58PM
(Associated Press Finance)
04:49PM
04:05PM
Nov-02-23 06:04AM
Nov-01-23 11:27PM
10:01AM
09:00AM
Oct-31-23 10:01AM
Oct-27-23 09:45AM
Oct-24-23 02:00PM
Oct-10-23 11:34AM
Sep-27-23 10:16AM
Sep-26-23 07:35PM
Sep-01-23 12:45PM
Aug-29-23 10:46AM
Aug-22-23 11:56AM
Aug-16-23 12:45PM
07:57AM
Aug-11-23 12:00PM
Aug-10-23 06:28AM
Aug-07-23 08:29AM
(American City Business Journals)
Aug-05-23 09:24AM
Aug-04-23 09:01AM
06:47AM
(Thomson Reuters StreetEvents)
Aug-03-23 09:00PM
05:35PM
04:28PM
04:01PM
Jul-21-23 11:20AM
Jul-20-23 12:00PM
10:29AM
Jul-18-23 11:40AM
06:37AM
Jul-17-23 06:51PM
04:37AM
Jul-11-23 03:00PM
Jul-10-23 10:00AM
Jul-07-23 12:00PM
Jun-29-23 08:30AM
Jun-27-23 01:26PM
Jun-21-23 08:00PM
Jun-15-23 09:30AM
Jun-14-23 10:02AM
Jun-12-23 09:55AM
Jun-07-23 07:06AM
Jun-05-23 12:00PM
May-24-23 06:51AM
May-17-23 12:45PM
12:20PM
09:55AM
May-09-23 06:49AM
(Thomson Reuters StreetEvents) +8.46%
May-08-23 05:35PM
04:33PM
04:03PM
May-04-23 01:26PM
May-02-23 12:00PM
Apr-27-23 05:35AM
Apr-26-23 08:00PM
Apr-24-23 12:00PM
Progyny, Inc. is a fertility benefits management company. It provides fertility solutions to employers, managing IUI, in vitro fertilization (IVF), egg freezing, and other fertility treatments. It operates through one segment: fertility and pharmacy benefits solutions. It also delivers treatment services and access to the firm's network of fertility specialist. The company was founded on April 3, 2008 and is headquartered in New York, NY.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Payson Norman Director Nov 23 '24 Sale 56.29 200 11,258 580,656 Nov 26 04:34 PM Livingston Mark S. CHIEF FINANCIAL OFFICER Apr 01 '24 Option Exercise 3.95 20,627 81,477 72,875 Apr 03 05:16 PM Schlanger David J Executive Chairman Apr 01 '24 Option Exercise 3.95 1,000 3,950 87,312 Apr 03 05:27 PM Livingston Mark S. CHIEF FINANCIAL OFFICER Apr 01 '24 Sale 37.62 11,165 419,979 50,119 Apr 03 05:16 PM Sturmer Michael E PRESIDENT Apr 01 '24 Sale 37.60 6,395 240,452 384,553 Apr 03 05:23 PM Schlanger David J Executive Chairman Apr 01 '24 Sale 37.52 1,000 37,522 83,631 Apr 03 05:27 PM Schlanger David J Executive Chairman Mar 27 '24 Option Exercise 3.95 71,272 281,845 157,584 Mar 29 07:01 PM Schlanger David J Executive Chairman Mar 27 '24 Sale 37.80 71,272 2,694,267 86,312 Mar 29 07:01 PM Schlanger David J Executive Chairman Mar 26 '24 Option Exercise 3.95 305 1,206 86,617 Mar 27 05:49 PM Schlanger David J Executive Chairman Mar 26 '24 Sale 37.50 305 11,439 86,312 Mar 27 05:49 PM Schlanger David J Executive Chairman Mar 25 '24 Option Exercise 3.95 2,597 10,270 88,909 Mar 27 05:49 PM Schlanger David J Executive Chairman Mar 25 '24 Sale 37.65 2,597 97,778 86,312 Mar 27 05:49 PM Schlanger David J Executive Chairman Mar 21 '24 Option Exercise 3.95 5,826 23,039 92,138 Mar 25 06:42 PM Schlanger David J Executive Chairman Mar 21 '24 Sale 37.74 5,826 219,877 86,312 Mar 25 06:42 PM Livingston Mark S. CHIEF FINANCIAL OFFICER Mar 01 '24 Option Exercise 3.95 22,000 86,900 65,647 Mar 05 05:04 PM Livingston Mark S. CHIEF FINANCIAL OFFICER Mar 01 '24 Sale 36.64 12,610 461,977 38,254 Mar 05 05:04 PM Sturmer Michael E PRESIDENT Mar 01 '24 Sale 36.63 11,009 403,260 141,738 Mar 05 04:57 PM Sturmer Michael E PRESIDENT Feb 06 '24 Sale 40.00 2,260 90,400 158,532 Feb 08 06:53 PM Schlanger David J Executive Chairman Feb 05 '24 Option Exercise 3.95 20,000 79,090 106,312 Feb 07 06:38 PM Schlanger David J Executive Chairman Feb 05 '24 Sale 38.50 20,000 769,928 86,312 Feb 07 06:38 PM Schlanger David J Executive Chairman Feb 02 '24 Option Exercise 3.95 30,000 118,635 116,312 Feb 05 06:51 PM Schlanger David J Executive Chairman Feb 02 '24 Sale 38.92 30,000 1,167,490 86,312 Feb 05 06:51 PM Schlanger David J Executive Chairman Feb 01 '24 Option Exercise 3.95 30,000 118,635 116,312 Feb 05 06:51 PM Livingston Mark S. CHIEF FINANCIAL OFFICER Feb 01 '24 Option Exercise 3.95 22,000 86,900 68,871 Feb 05 07:03 PM Schlanger David J Executive Chairman Feb 01 '24 Sale 38.29 30,000 1,148,635 86,312 Feb 05 06:51 PM Livingston Mark S. CHIEF FINANCIAL OFFICER Feb 01 '24 Sale 37.84 12,651 478,767 43,871 Feb 05 07:03 PM Sturmer Michael E PRESIDENT Feb 01 '24 Sale 37.89 6,395 242,307 160,792 Feb 05 06:57 PM Schlanger David J Executive Chairman Jan 08 '24 Option Exercise 3.95 66,002 261,005 152,314 Jan 10 06:31 PM Schlanger David J Executive Chairman Jan 08 '24 Sale 37.88 66,002 2,500,156 86,312 Jan 10 06:31 PM Livingston Mark S. CHIEF FINANCIAL OFFICER Jan 02 '24 Option Exercise 3.95 22,000 86,900 71,871 Jan 05 06:01 AM Schlanger David J Executive Chairman Jan 02 '24 Option Exercise 3.95 13,998 55,355 102,437 Jan 04 06:30 PM Schlanger David J Executive Chairman Jan 02 '24 Sale 37.58 13,998 526,024 88,439 Jan 04 06:30 PM Livingston Mark S. CHIEF FINANCIAL OFFICER Jan 02 '24 Sale 36.59 12,368 452,540 46,871 Jan 05 06:01 AM Sturmer Michael E PRESIDENT Jan 02 '24 Sale 36.81 6,395 235,400 167,187 Jan 04 06:42 PM Schlanger David J Executive Chairman Dec 27 '23 Option Exercise 3.95 76,031 300,665 164,470 Dec 28 08:19 PM Schlanger David J Executive Chairman Dec 27 '23 Sale 37.66 76,031 2,863,525 88,439 Dec 28 08:19 PM Schlanger David J Executive Chairman Dec 26 '23 Option Exercise 3.95 80,000 316,360 168,439 Dec 28 08:19 PM Schlanger David J Executive Chairman Dec 26 '23 Sale 37.93 80,000 3,034,760 88,439 Dec 28 08:19 PM Schlanger David J Executive Chairman Dec 22 '23 Option Exercise 3.95 80,000 316,360 168,439 Dec 22 04:40 PM Schlanger David J Executive Chairman Dec 22 '23 Sale 38.11 80,000 3,048,408 88,439 Dec 22 04:40 PM Schlanger David J Executive Chairman Dec 21 '23 Option Exercise 3.95 80,000 316,360 168,439 Dec 22 04:40 PM Schlanger David J Executive Chairman Dec 21 '23 Sale 37.65 80,000 3,011,952 88,439 Dec 22 04:40 PM Schlanger David J Executive Chairman Dec 20 '23 Option Exercise 3.95 2,906 11,492 91,345 Dec 22 04:40 PM Schlanger David J Executive Chairman Dec 20 '23 Sale 37.50 2,906 108,987 88,439 Dec 22 04:40 PM Schlanger David J Executive Chairman Dec 14 '23 Option Exercise 3.95 1,063 4,204 89,502 Dec 18 07:39 PM Schlanger David J Executive Chairman Dec 14 '23 Sale 37.53 1,063 39,894 88,439 Dec 18 07:39 PM GORDON KEVIN K Director Dec 11 '23 Sale 35.93 2,500 89,825 9,854 Dec 13 07:06 PM Livingston Mark S. CHIEF FINANCIAL OFFICER Dec 01 '23 Option Exercise 3.95 44,000 173,800 102,377 Dec 05 07:44 PM Livingston Mark S. CHIEF FINANCIAL OFFICER Dec 01 '23 Sale 34.62 25,087 868,512 49,983 Dec 05 07:44 PM Sturmer Michael E PRESIDENT Dec 01 '23 Sale 34.13 12,696 433,314 173,806 Dec 05 07:49 PM TPG GP A, LLC Former 10% Owner Aug 07 '23 Sale 41.08 2,900,000 119,132,000 6,350,000 Aug 09 04:42 PM Anevski Peter CHIEF EXECUTIVE OFFICER Jul 14 '23 Option Exercise 3.95 17,990 71,060 225,937 Jul 18 04:27 PM Anevski Peter CHIEF EXECUTIVE OFFICER Jul 14 '23 Sale 38.95 17,990 700,710 207,947 Jul 18 04:27 PM Anevski Peter CHIEF EXECUTIVE OFFICER Jul 14 '23 Sale 38.95 2,096 81,639 1 Jul 18 04:27 PM Anevski Peter CHIEF EXECUTIVE OFFICER Jul 13 '23 Option Exercise 3.95 32,000 126,400 239,947 Jul 14 04:01 PM Schlanger David J Executive Chairman Jul 13 '23 Option Exercise 0.91 67,457 61,386 138,263 Jul 14 04:02 PM Schlanger David J Executive Chairman Jul 13 '23 Sale 38.95 67,457 2,627,450 70,806 Jul 14 04:02 PM Anevski Peter CHIEF EXECUTIVE OFFICER Jul 13 '23 Sale 38.94 32,000 1,246,080 207,947 Jul 14 04:01 PM Anevski Peter CHIEF EXECUTIVE OFFICER Jul 13 '23 Sale 38.94 8,000 311,520 2,097 Jul 14 04:01 PM Anevski Peter CHIEF EXECUTIVE OFFICER Jul 12 '23 Option Exercise 3.95 23,572 93,109 231,519 Jul 14 04:01 PM Schlanger David J Executive Chairman Jul 12 '23 Option Exercise 0.91 38,687 35,205 109,493 Jul 14 04:02 PM Schlanger David J Executive Chairman Jul 12 '23 Sale 38.64 38,687 1,494,866 70,806 Jul 14 04:02 PM Anevski Peter CHIEF EXECUTIVE OFFICER Jul 12 '23 Sale 38.64 23,572 910,822 207,947 Jul 14 04:01 PM Anevski Peter CHIEF EXECUTIVE OFFICER Jul 12 '23 Sale 38.64 4,890 188,950 10,097 Jul 14 04:01 PM Anevski Peter CHIEF EXECUTIVE OFFICER Jul 03 '23 Option Exercise 3.95 6,439 25,434 222,363 Jul 06 04:01 PM Schlanger David J Executive Chairman Jul 03 '23 Option Exercise 0.91 18,856 17,159 92,343 Jul 06 04:02 PM Schlanger David J Executive Chairman Jul 03 '23 Sale 38.76 18,856 730,859 73,487 Jul 06 04:02 PM Anevski Peter CHIEF EXECUTIVE OFFICER Jul 03 '23 Sale 38.78 6,439 249,704 215,924 Jul 06 04:01 PM Anevski Peter CHIEF EXECUTIVE OFFICER Jul 03 '23 Sale 38.78 1,610 62,436 14,987 Jul 06 04:01 PM Scott Cheryl Director Jun 27 '23 Sale 37.27 1,170 43,606 9,744 Jul 07 05:15 PM Anevski Peter CHIEF EXECUTIVE OFFICER Jun 07 '23 Option Exercise 3.95 16,000 63,200 231,924 Jun 08 08:00 PM Anevski Peter CHIEF EXECUTIVE OFFICER Jun 07 '23 Sale 40.97 16,000 655,512 215,924 Jun 08 08:00 PM Anevski Peter CHIEF EXECUTIVE OFFICER Jun 07 '23 Sale 40.97 4,000 163,878 16,597 Jun 08 08:00 PM Anevski Peter CHIEF EXECUTIVE OFFICER Jun 06 '23 Option Exercise 3.95 16,000 63,200 231,924 Jun 07 06:22 PM Anevski Peter CHIEF EXECUTIVE OFFICER Jun 06 '23 Sale 41.01 16,000 656,086 215,924 Jun 07 06:22 PM Anevski Peter CHIEF EXECUTIVE OFFICER Jun 06 '23 Sale 41.01 4,000 164,021 20,597 Jun 07 06:22 PM Anevski Peter CHIEF EXECUTIVE OFFICER Jun 05 '23 Option Exercise 3.95 16,000 63,200 231,924 Jun 07 06:22 PM Schlanger David J Executive Chairman Jun 05 '23 Option Exercise 0.91 41,666 37,916 115,153 Jun 07 06:23 PM Schlanger David J Executive Chairman Jun 05 '23 Sale 40.00 41,666 1,666,824 73,487 Jun 07 06:23 PM Anevski Peter CHIEF EXECUTIVE OFFICER Jun 05 '23 Sale 40.00 16,000 640,057 215,924 Jun 07 06:22 PM Anevski Peter CHIEF EXECUTIVE OFFICER Jun 05 '23 Sale 40.00 4,000 160,014 24,597 Jun 07 06:22 PM Anevski Peter CHIEF EXECUTIVE OFFICER Jun 02 '23 Option Exercise 3.95 16,000 63,200 231,924 Jun 05 05:08 PM Schlanger David J Executive Chairman Jun 02 '23 Option Exercise 0.91 41,667 37,917 115,154 Jun 05 04:48 PM Schlanger David J Executive Chairman Jun 02 '23 Sale 38.68 41,667 1,611,680 73,487 Jun 05 04:48 PM Anevski Peter CHIEF EXECUTIVE OFFICER Jun 02 '23 Sale 38.67 16,000 618,720 215,924 Jun 05 05:08 PM Anevski Peter CHIEF EXECUTIVE OFFICER Jun 02 '23 Sale 38.67 4,000 154,680 28,597 Jun 05 05:08 PM Anevski Peter CHIEF EXECUTIVE OFFICER Jun 01 '23 Option Exercise 3.95 16,000 63,200 231,924 Jun 05 05:08 PM Schlanger David J Executive Chairman Jun 01 '23 Option Exercise 0.91 41,667 37,917 115,154 Jun 05 04:48 PM Schlanger David J Executive Chairman Jun 01 '23 Sale 37.55 41,667 1,564,431 73,487 Jun 05 04:48 PM Anevski Peter CHIEF EXECUTIVE OFFICER Jun 01 '23 Sale 37.55 16,000 600,850 215,924 Jun 05 05:08 PM Anevski Peter CHIEF EXECUTIVE OFFICER Jun 01 '23 Sale 37.55 4,000 150,212 32,597 Jun 05 05:08 PM GORDON KEVIN K Director May 24 '23 Sale 38.24 1,410 53,918 12,354 May 26 05:03 PM Anevski Peter CHIEF EXECUTIVE OFFICER May 16 '23 Option Exercise 3.95 4,608 18,202 220,532 May 18 07:21 PM Anevski Peter CHIEF EXECUTIVE OFFICER May 16 '23 Sale 35.94 4,608 165,612 215,924 May 18 07:21 PM Anevski Peter CHIEF EXECUTIVE OFFICER May 16 '23 Sale 35.94 1,153 41,439 36,597 May 18 07:21 PM Anevski Peter CHIEF EXECUTIVE OFFICER May 15 '23 Option Exercise 3.95 32,000 126,400 247,924 May 16 05:29 PM Anevski Peter CHIEF EXECUTIVE OFFICER May 15 '23 Sale 36.24 32,000 1,159,680 215,924 May 16 05:29 PM Anevski Peter CHIEF EXECUTIVE OFFICER May 15 '23 Sale 36.24 8,000 289,920 31,655 May 16 05:29 PM Anevski Peter CHIEF EXECUTIVE OFFICER May 12 '23 Option Exercise 3.95 32,000 126,400 247,924 May 16 05:29 PM Anevski Peter CHIEF EXECUTIVE OFFICER May 12 '23 Sale 36.30 32,000 1,161,600 215,924 May 16 05:29 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite